Literature DB >> 1892076

Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction.

K G Oldroyd1, M P Pye, S G Ray, J Christie, I Ford, S M Cobbe, H J Dargie.   

Abstract

In a double-blind study, 99 patients (82 men, age range 40 to 75 years) with acute myocardial infarction (AMI) were randomly assigned to receive captopril or placebo. Treatment began within 24 hours of admission. Serial echocardiographic measurements of endocardial segment lengths and left ventricular (LV) volumes, and ejection fractions were obtained. The 2 groups were matched at baseline except for an excess of previous AMI in the placebo group (13 of 50 vs 2 of 49 patients, p = 0.002). The increase in anterior segment length, from baseline to 2 months, was significantly less in the captopril than in the placebo group (2.8 +/- 1.6 vs 10.4 +/- 2.4mm, 95% confidence interval [CI] -13.5 to -1.7, p = 0.01). The increase in posterior segment length was also less in the captopril group, but the difference was not significant (3.2 +/- 1.2 vs 7.0 +/- 1.8mm, 95% CI -8.0 to 0.5, p = 0.08). Fewer patients in the captopril group demonstrated increases in segment length greater than 2 standard deviations of the measurement error (14 of 70 [20%] vs 29 of 72 [40%] patients, p = 0.009). In patients with anterior AMI, the infarct-containing anterior segment length increased by 4.5 +/- 2.3 mm in the captopril versus 12.4 +/- 3.1 mm in the placebo group (95% CI -15.7 to -0.2, p = 0.046), and fewer patients in the captopril group demonstrated infarct expansion (6 of 20 [30%] vs 13 of 21 [62%] patients, p = 0.04).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1892076     DOI: 10.1016/0002-9149(91)90641-w

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

Review 1.  When to start an ACE inhibitor and in whom.

Authors:  P A Wilson
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

Review 2.  Should angiotensin converting enzyme (ACE) inhibitors be used routinely after infarction? Perspectives from the Survival and Ventricular Enlargement (SAVE) trial.

Authors:  M S Sutton
Journal:  Br Heart J       Date:  1994-02

3.  Change in ST segment elevation 60 minutes after thrombolytic initiation predicts clinical outcome as accurately as later electrocardiographic changes.

Authors:  I F Purcell; N Newall; M Farrer
Journal:  Heart       Date:  1997-11       Impact factor: 5.994

Review 4.  A risk-benefit assessment of ACE inhibitor therapy post-myocardial infarction.

Authors:  C Borghi; E Ambrosioni
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

Review 5.  Clinical aspects of ACE inhibition in patients with acute myocardial infarction.

Authors:  C Borghi; E Ambrosioni
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

Review 6.  Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1995-09       Impact factor: 3.923

7.  Early vasodilator treatment in myocardial infarction: appropriate for the majority or minority?

Authors:  A D Hargreaves; T Kolettis; A J Jacob; L L Flint; L W Turnbull; A L Muir; N A Boon
Journal:  Br Heart J       Date:  1992-10

8.  Activation and inhibition of the endogenous opioid system in human heart failure.

Authors:  K G Oldroyd; C E Gray; R Carter; K Harvey; W Borland; G Beastall; S M Cobbe
Journal:  Br Heart J       Date:  1995-01

9.  Do radionuclide and echocardiographic techniques give a universal cut off value for left ventricular ejection fraction that can be used to select patients for treatment with ACE inhibitors after myocardial infarction?

Authors:  S G Ray; M J Metcalfe; K G Oldroyd; M Pye; W Martin; J Christie; H J Dargie; S M Cobbe
Journal:  Br Heart J       Date:  1995-05

10.  Coenzyme Q10 Modulates Remodeling Possibly by Decreasing Angiotensin-Converting Enzyme in Patients with Acute Coronary Syndrome.

Authors:  Ram B Singh; Jan Fedacko; Viliam Mojto; Dominik Pella
Journal:  Antioxidants (Basel)       Date:  2018-07-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.